CURE Pharmaceutical Holding Corp. (CURR)
| Market Cap | 69.20M |
| Revenue (ttm) | 1.08M |
| Net Income (ttm) | -15.04M |
| Shares Out | 41.34M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.30 |
| Previous Close | $1.34 |
| Change ($) | -0.04 |
| Change (%) | -2.99% |
| Day's Open | 1.34 |
| Day's Range | 1.26 - 1.43 |
| Day's Volume | 56,857 |
| 52-Week Range | 0.96 - 2.85 |
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development compa...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness produc...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Closes $10 Million Financing
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by br...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October.
- CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT -
SHERMAN OAKS, Calif.--(BUSINESS WIRE)-- #Beauty--Sera Labs, a Leader in the CBD Industry to be acquired by CURE Pharmaceutical in a $20 Million Transaction
Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology Significantly higher serum concentration and absorption Showcases CUREfo...
OXNARD, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufactu...
- Jonathan Berlent Appointed to Newly Created Role - - Jonathan Berlent Appointed to Newly Created Role -
OXNARD, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR), an innovative drug delivery company that is developing novel ways to deliver active ingredien...
About CURR
CURE Pharmaceutical Holding, an integrated drug delivery and development company, focuses on improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. The company is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. It offers CURE 3068 (CUREfilm Sleep), a melatonin-containing sleep aid CUREfilm oral dissolving film (ODF) that is used as a dietary supplement under the brand name ID Life Sleep Strips; and CURE... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2011 |
| CEO Robert Davidson | Employees 18 |
| Stock Exchange OTCMKTS | Ticker Symbol CURR |
Financial Performance
In 2019, CURR's revenue was $623,000, an increase of 6.68% compared to the previous year's $584,000. Losses were -$21.36 million, 105.4% more than in 2018.